OTCMKTS:OXBDF - Oxford BioMedica Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Oxford BioMedica plc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $6.06 0.00 (0.00 %) (As of 03/27/2020 04:00 PM ET) Add Compare Today's Range$6.06Now: $6.06▼$6.0650-Day Range$4.51MA: $7.35▼$8.4052-Week Range$4.51Now: $6.06▼$10.02Volume10 shsAverage Volume320 shsMarket Capitalization$398.02 millionP/E Ratio40.40Dividend YieldN/ABeta0.8 ProfileAnalyst RatingsAdvanced ChartHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments. Its LentiVector platform technology integrates genes into non-dividing cells in the brain and retinal cells in the eye, as well as accommodates multiple therapeutic genes. The company's products under development include OXB-102 that is in Phase I/IIa study preparation for the treatment of Parkinson's disease; OXB-202, which is in a Phase I/IIa trial preparation for the prevention of corneal graft rejection; and OXB-302, a gene-based cancer immunotherapy product that has completed pre-clinical development for use in the treatment of a range of cancers, as well as OXB-201 that has completed Phase I trial for the treatment of wet age-related macular degeneration and diabetic retinopathy. It is also developing gene-based therapies, such as SAR 422459 that is in a Phase II trial for the treatment of Stargardt disease; and SAR 421869, which is in Phase I/II trial for the treatment of Usher syndrome 1B. The company has partnerships with Novartis, Sanofi, GlaxoSmithKline, Bioverativ, Orchard Therapeutics, GC LabCell, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations, Immune Design, and Microsoft. Oxford BioMedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.Read More Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Private households Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:OXBDF Previous SymbolNASDAQ:OXBDF CUSIPN/A CIKN/A Webhttp://www.oxfordbiomedica.co.uk/ Phone44-18-6578-3000Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E Ratio40.40 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$89.14 million Price / Sales4.47 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees432 Outstanding Shares65,680,000Market Cap$398.02 million Next Earnings Date4/2/2020 (Estimated) OptionableNot Optionable Receive OXBDF News and Ratings via Email Sign-up to receive the latest news and ratings for OXBDF and its competitors with MarketBeat's FREE daily newsletter. OTC:OXBDF Rates by TradingView Oxford BioMedica (OTCMKTS:OXBDF) Frequently Asked Questions How has Oxford BioMedica's stock been impacted by COVID-19 (Coronavirus)? Oxford BioMedica's stock was trading at $7.7250 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, OXBDF shares have decreased by 21.6% and is now trading at $6.06. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Oxford BioMedica? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oxford BioMedica in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Oxford BioMedica. When is Oxford BioMedica's next earnings date? Oxford BioMedica is scheduled to release its next quarterly earnings announcement on Thursday, April 2nd 2020. View our earnings forecast for Oxford BioMedica. What price target have analysts set for OXBDF? 1 analysts have issued 1-year price objectives for Oxford BioMedica's stock. Their forecasts range from $14.50 to $14.50. On average, they expect Oxford BioMedica's stock price to reach $14.50 in the next twelve months. This suggests a possible upside of 139.3% from the stock's current price. View analysts' price targets for Oxford BioMedica. What are Wall Street analysts saying about Oxford BioMedica stock? Here are some recent quotes from research analysts about Oxford BioMedica stock: 1. According to Zacks Investment Research, "Oxford BioMedica Plc is a gene and cell therapy company which focused on developing life changing treatments for serious diseases. Oxford BioMedica Plc is headquartered in Oxford, the United Kingdom. " (3/24/2020) 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and 1450p price target. Our price target is based on our clinical net present value (NPV) model, which derives value primarily from Novartis’ CTL019 (lentiviral production and royalty). This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (9/4/2019) Has Oxford BioMedica been receiving favorable news coverage? News coverage about OXBDF stock has been trending positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Oxford BioMedica earned a daily sentiment score of 2.1 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near future. View the latest news aboutOxford BioMedica. Who are some of Oxford BioMedica's key competitors? Some companies that are related to Oxford BioMedica include Essentra (FLRAF), DeNA (DNACF), WOOLWORTHS HOLD/GDR (WLWHY), DOMINOS PIZZA U/ADR (DPUKY), INDRA SISTEMAS/ADR (ISMAY), Chow Tai Fook Jewellery Group (LFSYY), Acacia Mining (ABGLF), Loomis (LOIMF), TOKUYAMA CORP/ADR (TKYMY), Clinigen Group (CLIGF), BPOST SA/ADR (BPOSY), OUTOKUMPU OYJ/ADR (OUTKY), AMS AG/ADR (AMSSY), FIRSTGROUP/ADR (FGROY) and Pharma Mar (PHMMF). What other stocks do shareholders of Oxford BioMedica own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oxford BioMedica investors own include Oxford BioMedica (OXB), Petra Diamonds (PDL), Ferrexpo (FXPO), Fresenius Medical Care AG & Co. KGaA (FME), Nokia Oyj (NOKIA), Hummingbird Resources (HUM), Royal Dutch Shell (RDSB), Rapid7 (RPD), Lloyds Banking Group (LLOY) and CSX (CSX). Who are Oxford BioMedica's key executives? Oxford BioMedica's management team includes the following people: Mr. John Dawson, CEO & Exec. Director (Age 59)Mr. Stuart Paynter, CFO & DirectorMr. Timothy William Watts, Exec. Officer (Age 61)Mr. Peter Nolan, Consultant (Age 66)Mr. Nick Page, Chief Operations Officer What is Oxford BioMedica's stock symbol? Oxford BioMedica trades on the OTCMKTS under the ticker symbol "OXBDF." How do I buy shares of Oxford BioMedica? Shares of OXBDF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Oxford BioMedica's stock price today? One share of OXBDF stock can currently be purchased for approximately $6.06. How big of a company is Oxford BioMedica? Oxford BioMedica has a market capitalization of $398.02 million and generates $89.14 million in revenue each year. Oxford BioMedica employs 432 workers across the globe. View additional information about Oxford BioMedica. What is Oxford BioMedica's official website? The official website for Oxford BioMedica is http://www.oxfordbiomedica.co.uk/. How can I contact Oxford BioMedica? Oxford BioMedica's mailing address is Windrush Court Transport Way, Oxford X0, OX4 6LT. The company can be reached via phone at 44-18-6578-3000. MarketBeat Community Rating for Oxford BioMedica (OTCMKTS OXBDF)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 83 (Vote Outperform)Underperform Votes: 97 (Vote Underperform)Total Votes: 180MarketBeat's community ratings are surveys of what our community members think about Oxford BioMedica and other stocks. Vote "Outperform" if you believe OXBDF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OXBDF will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/28/2020 by MarketBeat.com StaffFeatured Article: Hedge Funds - How They Work For Investors
